



1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Nagy, et al.

Serial No: 10/001,934

Filed: November 15, 2001

For: Human Polypeptides Causing or
Leading to the Killing of Cells
Including Lymphoid Tumor Cells

Attorney Docket No. GPCG-P01-003

Art Unit: 1642

Examiner: Canella, Karen A

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

April 28, 2004

Date of Signature
and of Mail Deposit


Evelyn M. Friel

Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

REPLY UNDER 37 CFR §1.121

Sir:

This amendment is being filed in reply to the Notice of Non-Compliant Amendment, mailed April 19, 2004, in connection with the Reply to Office Action in the above application. The Examiner stated that the amendment to the claims filed on January 26, 2004 fails to include claim 87. Applicants respectfully submit that claim 87 is included in the amendment filed on January 26, 2004. Applicants have amended the identifier of claim 87 to comply with the requirements of 37 CFR 1.121(c) and hereby submit the revised amendment to the claims with the complete reply.

CONCLUSION

In view of the foregoing re-submission, Applicants submit that the Reply is in compliance with 37 CFR 1.121. The re-submission is being filed within the statutory one-month time period. Should an extension of time be required, Applicants hereby petition for same and request that the extension fee and any other fee required for timely consideration of this submission be charged to **Deposit Account No. 18-1945, Order No. GPCG-P01-003**

Respectfully Submitted,

Date: April 28, 2004

Customer No: 28120
Docketing Specialist
Ropes & Gray
One International Place
Boston, MA 02110
Phone: 617-951-7000
Fax: 617-951-7050



Weishi Li, Ph.D.
Reg. No. 53, 217